Disease · MONDO_0004627
Comparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 19 of 19
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 3 mg/kg of Lirentelimab (AK002) vs Placebo: Subjects Achieving Mean Eosinophil Count ≤1 Cell/Hpf in 5 Highest Gastric Hpf and/or Mean Eosinophil Count ≤1 Cell/Hpf in 3 Highest Duodenal Hpf at Week 24 | 75 of 91 | 1 of 89 | 180 | NCT04322604 | Trial comparisons |
| 3 mg/kg of Lirentelimab (AK002) vs Placebo: Proportion of Tissue Eosinophil Responders at Week 24 | 77 of 91 | 4 of 89 | 180 | NCT04322604 | Trial comparisons |
| 3 mg/kg of Lirentelimab (AK002) vs Placebo: Number of Treatment Responders | 39 of 91 | 3 of 89 | 180 | NCT04322604 | Trial comparisons |
| 3 mg/kg of Lirentelimab (AK002) vs Placebo: Subjects Who Achieve ≥70% Reduction in TSS From Baseline to Weeks 23-24 | 26 of 91 | 18 of 89 | 180 | NCT04322604 | Trial comparisons |
| 3 mg/kg of Lirentelimab (AK002) vs Placebo: deaths from any cause | 0 of 91 | 0 of 89 | 180 | NCT04322604 | Trial comparisons |
| 3 mg/kg of Lirentelimab (AK002) vs Placebo: Subjects Who Achieve ≥50% Reduction in TSS From Baseline to Weeks 23-24 | 36 of 91 | 29 of 89 | 180 | NCT04322604 | Trial comparisons |
| 3 mg/kg of Lirentelimab (AK002) vs Placebo: serious adverse events | 7 of 91 | 5 of 89 | 180 | NCT04322604 | Trial comparisons |
| Main Study Active to Extension Study 3.0 mg/kg of Lirentelimab (AK002) vs Main Study Placebo to Extension Study 3.0 mg/kg of Lirentelimab (AK002): deaths from any cause | 1 of 84 | 0 of 75 | 159 | NCT04620811 | Trial comparisons |
| Main Study Active to Extension Study 3.0 mg/kg of Lirentelimab (AK002) vs Main Study Placebo to Extension Study 3.0 mg/kg of Lirentelimab (AK002): serious adverse events | 14 of 84 | 6 of 75 | 159 | NCT04620811 | Trial comparisons |
| Main Study Active to Extension Study 3.0 mg/kg of Lirentelimab (AK002) vs Main Study Placebo to Extension Study 3.0 mg/kg of Lirentelimab (AK002): Proportion of Tissue Eosinophil Responders | 48 of 52 | 52 of 54 | 106 | NCT04620811 | Trial comparisons |
| 3.0 mg/kg of Lirentelimab (AK002) vs Placebo: Subjects Who Achive ≥50% Reduction in TSS From Baseline to Weeks 23-24 | 13 of 46 | 14 of 47 | 93 | NCT04856891 | Trial comparisons |
| 3.0 mg/kg of Lirentelimab (AK002) vs Placebo: Proportion of Tissue Eosinophil Responders at Week 24 | 38 of 46 | 2 of 47 | 93 | NCT04856891 | Trial comparisons |
| 3.0 mg/kg of Lirentelimab (AK002) vs Placebo: Subjects Achieving Eosinophils Count ≤1 Cell/Hpf in 3 Highest Duodenal Hpf at Week 24 | 37 of 46 | 0 of 47 | 93 | NCT04856891 | Trial comparisons |
| 3.0 mg/kg of Lirentelimab (AK002) vs Placebo: Subjects Who Achieve ≥70% Reduction in TSS From Baseline to Weeks 23-24 | 11 of 46 | 8 of 47 | 93 | NCT04856891 | Trial comparisons |
| 3.0 mg/kg of Lirentelimab (AK002) vs Placebo: Number of Treatment Responders | 21 of 46 | 1 of 47 | 93 | NCT04856891 | Trial comparisons |
| 3.0 mg/kg of Lirentelimab (AK002) vs Placebo: deaths from any cause | 0 of 46 | 0 of 47 | 93 | NCT04856891 | Trial comparisons |
| 3.0 mg/kg of Lirentelimab (AK002) vs Placebo: serious adverse events | 2 of 46 | 1 of 47 | 93 | NCT04856891 | Trial comparisons |
| Main Study Active to Extension Study 1 to 3.0 mg/kg of AK002 vs Main Study Placebo to Extension Study 1 to 3.0 mg/kg of AK002: deaths from any cause | 0 of 37 | 0 of 21 | 58 | NCT03664960 | Trial comparisons |
| Main Study Active to Extension Study 1 to 3.0 mg/kg of AK002 vs Main Study Placebo to Extension Study 1 to 3.0 mg/kg of AK002: serious adverse events | 9 of 37 | 2 of 21 | 58 | NCT03664960 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004627/comparisons